MedTrace Logo

Cycloserine rTMS Plasticity Augmentation

NCT03432689 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-11-09

No results posted yet for this study

Summary

Transcranial magnetic stimulation (rTMS) is an investigational and therapeutic modality that impacts the connection strength between neurons by delivering patterned energy. In response to this patterned energy neurons fire and adapt by changing their connection strengths. This change in connection strengths is believed to be the underlying mechanism whereby this intervention has therapeutic benefit for this intervention in conditions such as depression. The purpose of this study is to test a means of enhancing the effect of rTMS using a medication (cycloserine) that has been shown to augment and stabilize activity dependent neuronal changes. The investigators wish to use the motor system, where the associated muscle response to brain stimulation can be measured, to probe activity dependent changes in connection strength between neurons.

Conditions

  • Motor Activity

Interventions

DEVICE

Transcranial Magnetic Stimulation

Single-pulse transcranial magnetic stimulation and theta-burst stimulation

DRUG

Cycloserine

Cycloserine 100mg

DRUG

Placebo Oral Tablet

Placebo capsule matched to cycloserine capsule

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Alexander McGirr, MD MSc · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-06
Primary Completion
2018-11-07
Completion
2018-11-07
FDA Drug
Yes
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03432689 on ClinicalTrials.gov